A Multicenter phase II study of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanved non-squamous non-small cell lung cancer
- Conditions
- advanved non-squamous non-small cell lung cancer
- Registration Number
- JPRN-UMIN000007386
- Lead Sponsor
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 28
Not provided
(1)Squamous cell carcinoma (2)Previously untreated with platinum-based chemotherapy as a first line treatment (3)Discontinued bevacizumab due to its toxicity during a first line treatment (4)Severe complications (5)Symptomatic brain metastasis (6)Tumor cavitation (7)History or complication of hemoptysis with 2.5mL per time or more (8)Continuouis bloody phlegm more than 1 week. History or complication of bloody phlegm treated with continuous oral hemostatic agent. History or complication of bloody phlegm treated with infusional hemostatic agent. (9)Uncontrollable hypertension (10)History of GI perforation (11)Planning of surgery (12)Active concomitant malignancy (13)Severe drug allergy (14)Pregnancy or lactation (15)Severe psychological illness (16)History of thoracic radiotherapy (17)Systemic steroid treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method